Pacific Trade Invest NZ invites you to an important webinar on the FMCG industry in New Zealand. This will be of great ...

But 15 months on from La Roja lifting the trophy in Australia and New Zealand, how much has really changed for them ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

New Zealand’s banking landscape faces significant changes as new players target different segments, potentially disrupting ...

Enter: “Your Cancer Is Our Challenge,” a new initiative that GSK unveiled Tuesday with an aim of raising awareness of and ...

With no singular style and a range of microclimates, the one through line among distillers is a creative energy—and that they ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s centers of excellence, to ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

DelveInsight's Glucose Syrup Market Insights report provides the current and forecast market analysis, individual leading ...